Clinical Trial Update: A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) [Phase 3]

View source ↗

Summary

A Phase 3 follow-up study on long-term treatment with nintedanib in progressive fibrosing interstitial lung disease has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Fibrosing Interstitial Lung Disease

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Phase 3 | Status: COMPLETED | Results posted: 2023-09-13